The kinetics of competitive radioligand binding predicted by the law of mass action

HJ Motulsky and LC Mahan

Although equilibrium competitive radioligand binding studies are often used to characterize hormone and neurotransmitter receptors, the kinetics of such experiments have not been extensively explored. The interactions of the radioligand and competitor with the receptors can be described by two differential equations which can be solved to yield a single equation describing the binding of the radioligand as a function of time. This equation has several applications: First, it can be used to simulate competitive binding reactions under defined conditions. Second, fitting experimental data to this equation allows one to determine the association and dissociation rate constants of the competing ligand, parameters that cannot be derived from equilibrium experiments. Furthermore, this method can be used to determine the KI of the competing drug from data acquired before equilibrium is reached. Third, mathematical analysis of the binding equation allowed us to answer two specific questions regarding the kinetics of competitive radioligand binding: how long such an incubation takes to equilibrate, and how the IC50 varies over time. The answers to these questions depended, to a large extent, on the relative values of the dissociation rate constants of the radioligand and competitor, which can be determined as noted above. When the competitor dissociates from the receptors more rapidly than the radioligand, the IC50 first decreases and then increases, but never has a value less than the KI. At low radioligand concentrations, equilibrium is reached in the same amount of time required of the radioligand to dissociate completely from the receptors as determined in an "off-rate experiment." At higher concentrations of radioligand this time is halved. When the competitor dissociates from the receptor more slowly than does the radioligand, then the time required to equilibrate depends only on the dissociation rate constant of the competitor, and the IC50 decreases over time.

Volume 25, Issue 1, pp. 1-9, 01/01/1984
Copyright © 1984 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				C. E. Heise, S. K. Sullivan, and P. D. Crowe Scintillation Proximity Assay as a High-Throughput Method to Identify Slowly Dissociating Nonpeptide Ligand Binding to the GnRH Receptor J Biomol Screen, March 1, 2007; 12(2): 235 - 239. [Abstract] [PDF]

				K. Yan, L. Madden, A. E. Choudhry, C. S. Voigt, R. A. Copeland, and R. R. Gontarek Biochemical Characterization of the Interactions of the Novel Pleuromutilin Derivative Retapamulin with Bacterial Ribosomes Antimicrob. Agents Chemother., November 1, 2006; 50(11): 3875 - 3881. [Abstract] [Full Text] [PDF]

				A. A. Carter and S. J. Hill Characterization of Isoprenaline- and Salmeterol-Stimulated Interactions between {beta}2-Adrenoceptors and {beta}-Arrestin 2 Using {beta}-Galactosidase Complementation in C2C12 Cells J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 839 - 848. [Abstract] [Full Text] [PDF]

				J. G. Baker, I. P. Hall, and S. J. Hill Influence of Agonist Efficacy and Receptor Phosphorylation on Antagonist Affinity Measurements: Differences between Second Messenger and Reporter Gene Responses Mol. Pharmacol., September 1, 2003; 64(3): 679 - 688. [Abstract] [Full Text] [PDF]

				M. Gillard, C. Van Der Perren, N. Moguilevsky, R. Massingham, and P. Chatelain Binding Characteristics of Cetirizine and Levocetirizine to Human H1 Histamine Receptors: Contribution of Lys191 and Thr194 Mol. Pharmacol., February 1, 2002; 61(2): 391 - 399. [Abstract] [Full Text] [PDF]

				M. Waelbroeck Activation of Guanosine 5'-[{gamma}-35S]thio-triphosphate Binding through M1 Muscarinic Receptors in Transfected Chinese Hamster Ovary Cell Membranes: 1. Mathematical Analysis of Catalytic G Protein Activation Mol. Pharmacol., April 1, 2001; 59(4): 875 - 885. [Abstract] [Full Text]

				P. G. Strange Antipsychotic Drugs: Importance of Dopamine Receptors for Mechanisms of Therapeutic Actions and Side Effects Pharmacol. Rev., March 1, 2001; 53(1): 119 - 134. [Abstract] [Full Text] [PDF]

				S. R. J. Hoare and T. B. Usdin Tuberoinfundibular Peptide (7-39) [TIP(7-39)], a Novel, Selective, High-Affinity Antagonist for the Parathyroid Hormone-1 Receptor with No Detectable Agonist Activity J. Pharmacol. Exp. Ther., November 1, 2000; 295(2): 761 - 770. [Abstract] [Full Text]

				S. R. J. Hoare, G. de Vries, and T. B. Usdin Measurement of Agonist and Antagonist Ligand-Binding Parameters at the Human Parathyroid Hormone Type 1 Receptor: Evaluation of Receptor States and Modulation by Guanine Nucleotide J. Pharmacol. Exp. Ther., June 1, 1999; 289(3): 1323 - 1333. [Abstract] [Full Text]

				D. R. Groebe and S. N. Abramson Lophotoxin Is a Slow Binding Irreversible Inhibitor of Nicotinic Acetylcholine Receptors J. Biol. Chem., January 6, 1995; 270(1): 281 - 286. [Abstract] [Full Text] [PDF]